Loading quotes...

Forecast

The analysts' average price target is €526.29 (+6.66%). The median is €552.37 (+11.95%).

Buy
  49
Hold
  6
Sell
  1

Discussions in the community


  • Vertex aligns growth strategy with kidney medicine

    At the Morgan Stanley Healthcare Conference, Vertex presented its shift from a cystic fibrosis focus to a diversified pharma platform, with kidney medicine (Pove for IgA nephropathy, Inaxaplin for APOL1‑related kidney disease) as a central growth axis. Pove has a PDUFA date of Nov. 30 and Vertex reports productive payer discussions in the U.S.; GFR data were withheld to preserve global approval options. Inaxaplin is in the phase‑III AMPLITUDE study with an interim analysis in early 2025. Additional cystic fibrosis and gene‑editing programs continue to provide cash flow and growth potential, while approval, trial results and reimbursement remain risks. » More on de.investing.com


  • Vertex unveils strategy shift beyond cystic fibrosis

    At the Cantor Fitzgerald Healthcare Conference, Vertex announced plans to expand its business beyond cystic fibrosis into multiple pillars, focusing on pain, hematology, kidney diseases and rare endocrine disorders following the Crinetics acquisition. CASGEVY and JOURNAVX are expected to generate combined revenue of more than $500m in 2025; JOURNAVX already has 1.6m prescriptions in 2025 and access to 260m insured lives. The PDUFA date for povetacicept in IgA nephropathy is November 30, 2025; inaxaplin is progressing as planned in the phase‑III AMPLITUDE study with interim readouts in early 2027. Vertex emphasized strict acquisition criteria and sees peak sales potential of up to $5bn from Crinetics additions PALSONIFY and Atumelnant. » More on de.investing.com


  • Vertex focuses on kidney therapies as next growth engine

    Vertex is shifting to a broader business model and aims to grow beyond cystic fibrosis, particularly in kidney diseases. Key programs include Inaxaplin (AMPLITUDE) for APOL1-mediated diseases with an interim readout in Q1 2027, and Povetacicept for IgA nephropathy (PDUFA 30.11.2024). The integration of Crinetics adds PALSONIFY and Atumelnant to the portfolio; Vertex expects combined peak sales of about $5 billion and cites numerous catalysts over the next 12–24 months. JOURNAVX is showing prescription-side growth, but revenue realization remains temporarily dampened by reimbursement issues. » More on de.investing.com


  • Vertex Pharmaceuticals reaches an all-time high of $555.84

    Vertex Pharmaceuticals shares rose to an all-time high of $555.84, close to the 52-week high, with a market capitalization of about $139.72 billion. Over the past year the stock gained 39.95%, reflecting positive market sentiment and investor confidence. Several analysts reaffirmed or raised price targets (RBC $570, BMO $600, Bernstein SocGen $608, Wolfe Research $562) and highlighted potential beyond the cystic fibrosis business. However, an InvestingPro analysis classifies VRTX as overvalued relative to its fair value. » More on de.investing.com


  • Bernstein names Vertex biotech favorite after competing study fails

    Bernstein analyst Jeffrey Walch names Vertex a top pick after Sionna released negative topline data for SION-719 in a phase-2a study in cystic fibrosis. The failure of the add-on drug study reduces a key competitive threat to Vertex’s dominant cystic fibrosis business and strengthens the market position of Trikafta/Alyftrek. Walch also sees greater, previously underestimated potential for Vertex beyond the cystic fibrosis indication and expects that Atumelnant could become a meaningful competitor to Crenessity in congenital adrenal hyperplasia. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics
In 2022, Vertex Pharma has already paid €0.0893 in dividends. The last payout was in March 2022.

Financials

In the last quarter, Vertex Pharma had revenue of €3.04bn and net profit of €577.03m
(EUR) September 2026
YoY
Revenue 3.04bn 15.88%
Gross profit 2.57bn 13.46%
Net profit 577.03m 37.47%
EBITDA 723.41m 37.40%

Fundamentals

Metric Value
Market capitalization
€124.06bn
Number of shares
253.54m
52-week high/low
€516.64 - €374.55
Dividends No
Beta
0.32
P/E ratio
34.39
PEG ratio
3.71
P/B ratio
6.53
P/S ratio
10.51

Company profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Name
Vertex Pharma
CEO
Reshma Kewalramani
Headquarters Boston, ma
USA
Website
Sector
Health Care
Industry
Biotechnology
IPO
05/04/2018
Employees 6,400

Ticker symbols

Exchange Symbol
NASDAQ
VRTX
London Stock Exchange
0QZU.L
XETRA
VX1.DE
Frankfurt
VX1.F
DĂĽsseldorf
VX1.DU
Hamburg
VX1.HM
Milan
1VRTX.MI
London
0QZU.L
SIX
VRTX.SW
MĂĽnchen
VX1.MU
Wien
VRTX.VI
🍪

Parqet  uses cookies. Learn more